Study selection
Published or unpublished randomised controlled trials (RCTs) in any language were selected if they compared sildenafil with a placebo or alternative treatment in men with ED.
Data extraction
2 reviewers independently assessed the quality of studies (ie, allocation concealment, blinding, losses to follow up, and intention to treat analysis) and extracted data. Discrepancies were resolved by discussion. When trials were published in abstract form only, further information was requested from Pfizer. The main outcome was sexual function (questions 3 and 4 of the International Index of Erectile Function [IIEF]; responses were rated on a 5 point scale with 0 indicating no attempt at intercourse).
Main results
21 RCTs met the selection criteria; 3 were published as full reports. 1 RCT compared sildenafil with an alternative compound. All RCTs were double blind and > 80% of patients completed the studies. Studies included approximately 4000 men who had had ED for >6 months and were in stable relationships for > 6 months. 8 RCTs (mean follow up 14 wks) showed that sildenafil (25-200 mg) was better than placebo for increasing the frequency of penetration (IIEF question 3, range 3.2-4.0 for sildenafil and 1.9-2.3 for placebo, p < 0.001 for all RCTs) and improving maintenance of erection (IIEF question 4, range 2.9-3.9 for sildenafil and 1.6-2.1 for placebo, p < 0.001 for all RCTs). At a mean follow up of 10.8 weeks, more men on sildenafil than on placebo reported that treatment improved their erections (16 RCTs) (table).
Conclusion
In men with erectile dysfunction, sildenafil improves sexual and erectile function. 
COMMENTARY
The long time lag between the search for trials and publication has unfortunately already rendered this well conducted systematic review by Burls et al outdated. A Medline search yielded 27 additional published RCTs of sildenafil in men who were of diverse races and had ED of different aetiologies. However, these additional trials do not refute the consistency or direction of effect of the main results of this systematic review. A number needed to treat of 2-3 for the main outcome measure from this review justifies sildenafil's place as the first line treatment for men with ED. This endorsement does not come without its caveats. The main concern, not sufficiently addressed in this systematic review because of the paucity of data, relates to its cardiovascular safety. The available evidence suggests that in patients who have cardiac disease and are not on nitrates, sildenafil does not provoke ischaemia during exercise, 1 although sexual activity may still provoke adverse cardiac events. Clinicians prescribing the drug to men with known or suspected cardiac disease should adhere to recommendations aimed at minimising cardiovascular events. 2 3 The dangers of combination with recreational drugs and issues pertaining to HIV prevention also need to be addressed.
In one open label extension trial, up to 52 weeks of treatment did not diminish the efficacy of sildenafil in patients with ED and it remained well tolerated, 4 but more long term data are needed. Sildenafil is not an initiator of erections, and psychosexual counselling may need to be combined with sildenafil therapy to address misconceptions, interpersonal issues, and/or secondary psychological problems, irrespective of the aetiology of ED. In some settings, psychosexual counselling may in itself suffice to treat ED.
Regularly updated systematic reviews are required to keep pace with the rapid new developments in this field.
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